Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans.
Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans.
复制标题
DOI：
10.1016/j.jalz.2015.05.005
复制
发表时间：
2015-07
期刊：
影响因子：
--
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
Aisen PS;Petersen RC;Donohue M;Weiner MW;Alzheimer's Disease Neuroimaging Initiative
本文综述了阿尔茨海默病神经影像学倡议（ADNI）临床核心的现状，并总结了该项目下一阶段的计划。临床核心活动和计划是在核心领导和外部顾问讨论的基础上合成的。ADNI2的纵向数据提供了临床试验人群的自然历史数据，并继续为评估、轨迹模型和临床试验方法的改进和标准化提供信息，这些方法已扩展到散发性临床前AD。ADNI项目下一阶段的计划包括维持正常和轻度认知障碍队列的纵向随访，增加特定的临床队列，并纳入新的计算机认知评估和患者报告的结果。一个主要的假设是，阿尔茨海默病是一种逐渐进展的疾病，可以在症状前的长期阶段精确识别，在此期间，使用潜在的疾病调节剂进行干预可能是最有用的。
This paper reviews the current status of the Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. The longitudinal data in ADNI2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical AD. Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and MCI cohorts, augmenting specific clinical cohorts and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long pre-symptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.